Largest biotech by market cap
Amgen leads the 24 biotech ranked by market value, at ZAR 4.26T, ahead of Gilead Sciences (ZAR 3.63T) and Moderna (ZAR 1.44T). Figures as of 18 Nov 2026, 12:44 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenZAR 4.26T
- Median
- ZAR 178.4B
- Combined market value
- ZAR 14.6T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Market cap ↓ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | ZAR 4.26T | ZAR 7,875.55 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | ZAR 3.63T | ZAR 2,928.16 | 1.60% up | 33% up | ||
| 3 | ModernaMRNA · Health Care | ZAR 1.44T | ZAR 3,556.58 | 3.93% down | 755% up | ||
| 4 | argenxARGX · Health Care | ZAR 1.02T | ZAR 16,295.60 | 0.36% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | ZAR 637.6B | ZAR 4,313.13 | 0.34% down | 49% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | ZAR 605.2B | ZAR 2,797.97 | 2.50% down | 131% up | ||
| 7 | BioNTechBNTX · Health Care | ZAR 361.8B | ZAR 1,459.44 | 0.47% down | 16% down | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | ZAR 288.8B | ZAR 2,853.52 | 0.37% up | 20% up | ||
| 9 | ExelixisEXEL · Health Care | ZAR 287.5B | ZAR 1,178.07 | 2.09% up | 63% up | ||
| 10 | Bio-TechneTECH · Health Care | ZAR 196.2B | ZAR 1,249.10 | 0.22% down | 26% up | ||
| 11 | Halozyme TherapeuticsHALO · Health Care | ZAR 188.2B | ZAR 1,650.51 | 0.55% down | 37% up | ||
| 12 | Kymera TherapeuticsKYMR · Health Care | ZAR 178.4B | ZAR 2,089.92 | 3.44% down | 87% up | ||
| 13 | RepligenRGEN · Health Care | ZAR 178.3B | ZAR 2,789.20 | 0.37% down | 5% up | ||
| 14 | QiagenQGEN · Health Care | ZAR 176.7B | ZAR 855.61 | 0.12% down | 12% up | ||
| 15 | VaxcytePCVX · Health Care | ZAR 161.7B | ZAR 1,021.57 | 3.59% down | 22% up | ||
| 16 | Krystal BiotechKRYS · Health Care | ZAR 152.2B | ZAR 5,134.51 | 0.22% up | 46% up | ||
| 17 | Twist BioscienceTWST · Health Care | ZAR 127.7B | ZAR 1,926.19 | 6.63% up | 340% up | ||
| 18 | CG OncologyCGON · Health Care | ZAR 121.3B | ZAR 1,357.62 | 6.89% down | 85% up | ||
| 19 | ImmunovantIMVT · Health Care | ZAR 118.2B | ZAR 571.15 | 0.21% down | 43% up | ||
| 20 | ImmunityBioIBRX · Health Care | ZAR 114.5B | ZAR 107.66 | 4.68% up | 193% up | ||
| 21 | Kodiak SciencesKOD · Health Care | ZAR 108.9B | ZAR 1,664.78 | 3.90% down | 396% up | ||
| 22 | Scholar Rock HoldingSRRK · Health Care | ZAR 94.6B | ZAR 775.29 | 1.21% up | 14% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | ZAR 79.3B | ZAR 489.98 | 2.22% up | 88% up | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | ZAR 67B | ZAR 690.51 | 0.54% down | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 17.1982 ZAR).
Questions and answers
Which biotech rank first by market value?
Amgen (ZAR 4.26T), Gilead Sciences (ZAR 3.63T) and Moderna (ZAR 1.44T) are the top three of the 24 biotech ranked by market value as of 18 Nov 2026, 12:44 UTC.
How many biotech are in this ranking?
24 are ranked by market value.
What are these biotech worth together?
The 24 biotech ranked by market value have a combined market value of ZAR 14.6T as of 18 Nov 2026, 12:44 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by market cap”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech
Underlying data: Yahoo Finance; SEC EDGAR.